Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

480 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-07

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Since the first local case of COVID-19 confirmed on 4 Feb 2020, Hong Kong has already experienced 4 waves of COVID-19 surge, with more than 9000 cases reported. A number of vaccines have been shown to be efficacious against symptomatic and severe infection by inducing neutralizing antibody (NAB) against spike protein of the SARS-CoV-2 virus. However, the duration of protection and longevity of antibody response is unknown.

Health care workers (HCWs) who are planning to receive COVID-19 vaccine will be recruited. The level of antibody against spike protein by different quantitative assays will also be serially measured .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year

NCT04910971

COVID-19 Vaccine Corona Virus Infection Vaccine Adverse Reaction +3 more

UNKNOWN

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

NCT04775069

Chronic Liver Disease

COMPLETED PHASE4

Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19

NCT04496141

Covid19

COMPLETED

Effect of a Third COVID-19 Booster Among Health Care Workers

NCT05373459

COVID-19 Vaccines

COMPLETED

A Study to Evaluate Vaccines Against COVID-19 in the Real World

NCT04775056

Chronic Liver Disease Hepatic Carcinoma

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid-19 Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BNT162b2

Subjects who receive mRNA vaccine BNT162b2.

BNT162b2 Vaccine

Intervention Type BIOLOGICAL

Covid-19 BNT162b2 Vaccine

CoronaVac

Subjects who receive inactivated vaccine, CoronaVac.

CoronaVac Vaccine

Intervention Type BIOLOGICAL

CoronaVac Vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CoronaVac Vaccine

Intervention Type BIOLOGICAL

BNT162b2 Vaccine

Covid-19 BNT162b2 Vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Any staff, visiting doctor, nursing student of HKSH who are aged 18 or above
2. No contraindication for COVID-19 vaccination and plan to receive the intended dosages at the appropriate interval.
3. A baseline serology taken within 1 week before vaccination shows no evidence of recent infection.
4. No history of documented COVID-19 infection